196 related articles for article (PubMed ID: 36300528)
1. Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses.
Lu SC; Barry MA
Expert Opin Biol Ther; 2022 Nov; 22(11):1359-1378. PubMed ID: 36300528
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Adenoviruses for Cancer Therapy.
Tripodi L; Vitale M; Cerullo V; Pastore L
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802281
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in oncolytic adenovirus therapies for cancer.
Rosewell Shaw A; Suzuki M
Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
[TBL] [Abstract][Full Text] [Related]
4. Strategies for enhancing intratumoral spread of oncolytic adenoviruses.
Goradel NH; Negahdari B; Ghorghanlu S; Jahangiri S; Arashkia A
Pharmacol Ther; 2020 Sep; 213():107586. PubMed ID: 32479843
[TBL] [Abstract][Full Text] [Related]
5. Construction of targeted and armed oncolytic adenoviruses.
Doronin K; Shayakhmetov DM
Methods Mol Biol; 2012; 797():35-52. PubMed ID: 21948467
[TBL] [Abstract][Full Text] [Related]
6. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
[TBL] [Abstract][Full Text] [Related]
8. Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo.
Strauss R; Lieber A
Curr Opin Mol Ther; 2009 Oct; 11(5):513-22. PubMed ID: 19806499
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review).
Wang X; Zhong L; Zhao Y
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33760203
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic viruses: adenoviruses.
Niemann J; Kühnel F
Virus Genes; 2017 Oct; 53(5):700-706. PubMed ID: 28702840
[TBL] [Abstract][Full Text] [Related]
11. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
12. Current issues and future directions of oncolytic adenoviruses.
Yamamoto M; Curiel DT
Mol Ther; 2010 Feb; 18(2):243-50. PubMed ID: 19935777
[TBL] [Abstract][Full Text] [Related]
13. Cancer gene therapy with oncolytic adenoviruses.
Guse K; Hemminki A
J BUON; 2009 Sep; 14 Suppl 1():S7-15. PubMed ID: 19785073
[TBL] [Abstract][Full Text] [Related]
14. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations.
Shirazi MMA; Saedi TA; Moghaddam ZS; Nemati M; Shiri R; Negahdari B; Goradel NH
Pharmacol Ther; 2024 Apr; 256():108611. PubMed ID: 38387653
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy.
Xie D; Tian Y; Hu D; Wang Y; Yang Y; Zhou B; Zhang R; Ren Z; Liu M; Xu J; Dong C; Zhao B; Yang L
Signal Transduct Target Ther; 2023 Nov; 8(1):436. PubMed ID: 38016957
[TBL] [Abstract][Full Text] [Related]
17. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
[TBL] [Abstract][Full Text] [Related]
18. Mining the adenovirus "virome" for systemic oncolytics.
Barry MA; Weaver EA; Chen CY
Curr Pharm Biotechnol; 2012 Jul; 13(9):1804-8. PubMed ID: 21740366
[TBL] [Abstract][Full Text] [Related]
19. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
Zhang L; Hedjran F; Larson C; Perez GL; Reid T
Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
[TBL] [Abstract][Full Text] [Related]
20. Going viral: a review of replication-selective oncolytic adenoviruses.
Larson C; Oronsky B; Scicinski J; Fanger GR; Stirn M; Oronsky A; Reid TR
Oncotarget; 2015 Aug; 6(24):19976-89. PubMed ID: 26280277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
